Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Common Equity (2016 - 2025)

Vistagen Therapeutics' Common Equity history spans 11 years, with the latest figure at $50.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 37.23% year-over-year to $50.9 million; the TTM value through Dec 2025 reached $50.9 million, down 37.23%, while the annual FY2025 figure was $70.4 million, 38.41% down from the prior year.
  • Common Equity for Q4 2025 was $50.9 million at Vistagen Therapeutics, down from $66.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $123.3 million in Q4 2023 and bottomed at $6.8 million in Q2 2023.
  • The 4-year median for Common Equity is $80.7 million (2021), against an average of $76.1 million.
  • The largest annual shift saw Common Equity soared 1810.19% in 2021 before it crashed 45.84% in 2025.
  • A 4-year view of Common Equity shows it stood at $80.0 million in 2021, then skyrocketed by 54.15% to $123.3 million in 2023, then tumbled by 34.2% to $81.1 million in 2024, then tumbled by 37.23% to $50.9 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Common Equity are $50.9 million (Q4 2025), $66.3 million (Q3 2025), and $56.8 million (Q2 2025).